Rob Binney

Skills and experience

Rob Binney is currently the President and CEO of ShiraTronics, a pre-commercial neuromodulation company currently working on a novel new neurostimulation device focused on improving outcome for patients that suffer from chronic migraine. Prior to joining ShiraTronics, Rob served as the CEO of Alydia Health. He led the company to a $240M acquisition by Organon and was retained by the parent organization to lead through their transition, integration, and further corporate expansion.

Prior to Alydia Health, Rob was the Global Chief Commercial Officer of Intersect ENT, having joined pre-FDA approval in June of 2011. Under Rob’s leadership, Intersect ENT’s business grew from $0 to over $100M in annual sales and over $500M in cumulative sales. Prior to Intersect, Rob was one of the first 10 hires on the commercial team at AccessClosure and by the time he departed, was one of two sales leaders running the North American sales efforts of their $70M vascular sealing franchise.  Preceding his experience at AccessClosure, Rob worked for Boston Scientific.

Throughout the last decade Rob has provided strategic consulting services to several Bay Area startups, including Arrinex and NeoTract, was an Operating Partner for Revival Healthcare Capital, and has served on several boards including Galena Innovations, and Eyenuk, Inc, where he currently serves as Chairman of the Board.

Education

Rob holds a BA in Communications from the University of North Carolina at Chapel Hill.